- Nepali becomes youngest to climb world's 8,000m peaks
- Climate change made deadly Hurricane Helene more intense: study
- A US climate scientist sees hurricane Helene's devastation firsthand
- Padres edge Dodgers, Mets on the brink
- Can carbon credits help close coal plants?
- With EU funding, Tunisian farmer revives parched village
- Sega ninja game 'Shinobi' gets movie treatment
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- Three million UK children living below poverty line: study
- China's Jia brings film spanning love, change over decades to Busan
- Paying out disaster relief before climate catastrophe strikes
- Chinese shares drop on stimulus upset, Asia tracks Wall St higher
- SE Asian summit seeks progress on Myanmar civil war
- How climate funds helped Peru's women beekeepers stay afloat
- Nobel Peace Prize to be awarded as wars rage
- Pacific island nations swamped by global drug trade
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- Mozambique elects new president in tense vote
- The US economy is solid: Why are voters gloomy?
- Balkan summit to rally support for struggling Ukraine
- New stadium gives Real Madrid a headache
- Alonso, Manaea shine as 'Miracle Mets' blitz Phillies
- Harris, Trump trade blows in US election media blitz
- Harry's Bar in Paris drinks to US straw-poll centenary
- Osama bin Laden's son Omar banned from returning to France
- Afghan man arrested for plotting US election day attack
- Brazil lifts ban on Musk's X, ending standoff over disinformation
- Harris holds slight edge nationally over Trump: poll
- Chelsea edge Real Madrid in Women's Champions League, Lyon win
- Japan PM to dissolve parliament for 'honeymoon' snap election
- 'Diego Lives': Immersive Maradona exhibit hits Barcelona
- Brazil Supreme Court lifts ban on Musk's X
- Scientists sound AI alarm after winning physics Nobel
- Six-year-old girl among missing after Brazil landslide
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Mexico president rules out new 'war on drugs'
- Israeli defense minister postpones trip to Washington: Pentagon
- Europe skipper Donald in talks with Garcia over Ryder return
- Kenya MPs vote to impeach deputy president in historic move
- Former US coach Berhalter named Chicago Fire head coach
- New York Jets fire head coach Saleh: team
- Australia crush New Zealand in Women's T20 World Cup
- US states accuse TikTok of harming young users
- 'Evacuate now, now, now': Florida braces for next hurricane
- US Supreme Court skeptical of challenge to 'ghost guns' regulation
- Sparks fly as Orban berates EU 'elites' in parliament trip
- US finalizes rule to remove lead pipes within a decade
- Solanke hungry for second England cap after seven-year wait
Pfizer sees high demand for Covid-19 pill as profits jump
Pfizer executives said Tuesday they are confident of strong demand for the company's Covid-19 antiviral treatment amid easing pandemic rules as the big drugmaker reported another round of strong earnings.
The US pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its Covid-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.
Pfizer Chief Executive Albert Bourla said the company is seeing "very strong signs of increasing demand for Paxlovid as it remains one of the best tools we have."
Citing rising vaccine fatigue, Bourla said the company is also focused on a Covid-19 vaccine booster that provides immunity for a year.
"People are tired of the repeated booster, so it is extremely important to come to a vaccine that could be a yearly vaccine," Bourla told analysts on a conference call, adding that while the company has made progress on this front, "it's not technically easy to achieve."
"There's a tremendous pressure across the world to get our lives back," Bourla said of the social and political impetus to ease pandemic rules. "As a result of these things it's very clear that we will have waves" of Covid-19.
- 'Rebound' risk -
The US drugmaker reported first-quarter profits of $7.9 billion, up 61 percent, based on a 77 percent surge in revenues to $25.7 billion.
Pfizer lowered its full-year adjusted profits by 10 cents to $6.25 to $6.45 a share, due in part to currency movements.
But the company confirmed its full-year revenue forecast of about $100 billion, which is an approximately 23 percent increase on the 2021 level. More than half the revenues are expected to come from the Covid-19 vaccine and therapeutic.
Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.
In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.
The company expects to produce 120 million courses of the Paxlovid oral pills in 2022, with distribution programs scaling up in the United States and other markets.
The treatment has received emergency or conditional approval in 40 countries so far, the company said.
"What we are seeing is... there is demand for this product," said Pfizer biopharmaceuticals group president Angela Hwang, citing the removal of mask mandates as a factor in spreading cases.
"What we're also seeing is that we don't have any inventory on hand," Hwang said. "Every dose that we produce is being shipped out."
Pfizer executives said they were researching "rebound" Covid-19 cases in which some patients who took Paxlovid have reported renewed symptoms.
But company officials said the data thus far suggests that the amount of cases is small and may have to do with unusual patient characteristic rather than the drug itself.
The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.
But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.
Shares of Pfizer rose 1.7 percent to $49.17 in afternoon trading.
J.Williams--AMWN